Yüksel Ürün: New era for HER2-mutant lung cancer!
Apr 30, 2025, 09:09

Yüksel Ürün: New era for HER2-mutant lung cancer!

Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared on X:

“New era for HER2-mutant lung cancer!
Zongertinib delivered a 71% response rate, 12.4 months median PFS, and low-grade toxicity. No ILD reported.
Precision hitting its mark!”

Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

Authors: John V. Heymach et al.

Yüksel Ürün: New era for HER2-mutant lung cancer!

Read Also: New Paper Alert: Zongertinib in Previously Treated HER2-Mutant NSCLC. Beamion LUNG-1 Study Results